AccurEdit Therapeutics

Going beyond disease management

AccurEdit Therapeutics is a biotech company in Jiangsu, United States, founded in 2021. It has raised $75.0M across 2 rounds, most recently a $75.0M Series A in August 2023.

Headquarters
Jiangsu
Employees
51–200
Founded
2021
Business Model
B2B
Total Funding
$75.0M
Last Round
$75.0M Series AAug 2023
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 2 investors for this company. The full record is or through the API.

About

AccurEdit Therapeutics is committed to developing cures for severe and life-threatening diseases through in vivo gene editing. The company has established an industry-leading end-to-end technology platform focused on RNA synthesis, editing, and delivery technologies. In October 2023, AccurEdit became the first company in China to demonstrate safe and effective systemic CRISPR gene editing in humans. Its lead program ART001 is an LNP-delivered in vivo gene editing therapy and received FDA RMAT designation. AccurEdit follows a patient-oriented philosophy pursuing single-dose curative therapy via a highly efficient technology platform.

Summary

It lists 51–200 employees. It has raised $75.0M in total across 2 rounds, most recently a $75.0M Series A round in Aug 2023. Investors include Legend Capital and Cormorant Asset Management.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series ASeries AAug 2023
$75.0M

Sign up to see all 2 events

Funding: Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AccurEdit Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/accuredit-therapeutics"><img src="https://indexed.vc/api/badge/company/accuredit-therapeutics" alt="AccurEdit Therapeutics on Indexed.vc" width="260" height="76" /></a>